Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs LYFT Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while LYFT Inc trades at $16.61 (market cap $6.64B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.5× LYFT Inc's market cap, and LYFT Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | LYFT | |
|---|---|---|
Market Cap | $29.60B | $6.64B |
Sector | Health | Industrials |
52-Week High | $491.22 | $24.57 |
52-Week Low | $205.48 | $12.65 |
Enterprise Value | $27.56B | $6.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Lyft trades at $16.42, down 4.87% today, with a bullish technical outlook from moving averages but bearish oscillators. The company reported Q2 2026 revenue growth of 16.1% to a record $5.5 billion in gross bookings, though EPS missed estimates. Strong cash flow generation and expanding global rider base support fundamentals, while valuation ratios like P/E of 2.55 appear attractive relative to historical norms.
Lyft's outlook is mixed: robust revenue growth and cash flow provide upside potential, but earnings misses and competitive pressures from Uber pose risks. The stock offers value with a consensus price target of $19.17, representing 17% upside, though investors face headwinds from rising expenses and market share battles in the ride-hailing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
